Tadalafil, another FDA-approved PDE5 inhibitor for PAH treatment, effectively regulates smooth muscle contraction and promotes vasodilation in the pulmonary vasculature [36]. This evidence concerns the gene PDE5A and pulmonary arterial hypertension.